Invest in innovations that can transform clinical outcomes.
VentureHealth™ is a portal for accredited investors who want investment access to breakthrough innovations in the $2.5 trillion healthcare sector.
VentureHealth™ raises $2.6M for Rani Therapeutics, in a Series B, led by Google Ventures
Rani Therapeutics is developing technology to deliver biotherapeutics orally, removing the need for subcutaneous or intramuscular injections. The company has delivered a well-known, commercially available antibody in a pre-clinical model.
Azevan is about to enter Phase II trials for therapies to treat PTSD, ADHD and depression
This company has completed initial human studies for its first-in-class Vasopressin antagonists that are orally active, and cross the blood-brain barrier. Azevan's technology platform has demonstrated safety in humans, and robust activity in the brain.
Tiatros has launched its private, secure mobile health cloud for physicians, and UCSF is on board
This rapidly-growing venture allows healthcare providers, patients and related parties to share clinical information and coordinate activities through mobile devices. Physicians can view everything on their smart phone or iPad. Tiatros improves efficiency while lowering cost, and its sales are ahead of forecast.
Now any physician with a smart phone can have ultrasound. Yes, it's that simple - and FDA approved.
Mobisante is on a mission to make ultrasound imaging available at point-of-care to every physician in the world. Its cloud-enabled system integrates immediately into clinical workflow, with a handheld system that is 1/10 the cost of bulky, conventional equipment.
We raised $1.49M for Nfocus, which was acquired by Covidien in 2013.
This company was developing breakthrough solutions for neurovascular disease, which could change the standard of care for brain aneurysms. Covidien acquired Nfocus in 2013 based on preliminary data from its first human trial.
We raised $1.8M for the world's next billion-dollar blockbuster, now partnered with St. Jude Medical.
Spinal Modulation is already changing the way that pain is treated by blocking it at the dorsal root ganglia. Now growing rapidly in Europe, the company has demonstrated dramatic improvements in managing chronic, intractable pain even in challenging anatomical points, such as the foot.